Based on current evidence, a recommended diagnostic algorithm is proposed: (1) Initial screening with TFE3 IHC, acknowledging its utility as a sensitive but not entirely specific marker; (2) For cases showing positive or equivocal TFE3 IHC results, confirmation with a molecular method such as FISH or NGS is mandatory to establish the definitive diagnosis of ASPS. The gene discussed is TFE3; the disease is alveolar soft part sarcoma.